Clinical Trials
153 trialsReduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Duke University
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
Incyte Corporation
ACHIEVE
TC Biopharm
5
Institut Curie
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
Weill Medical College of Cornell University
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Memorial Sloan Kettering Cancer Center
Cromoglicate in Mastocytosis
LEO Pharma
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
M.D. Anderson Cancer Center
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Incyte Corporation
Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis
Mayo Clinic
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Weill Medical College of Cornell University
PONS
GWT-TUD GmbH
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
GVAX vs. Placebo for MDS/AML After Allo HSCT
Dana-Farber Cancer Institute
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
University of Utah
T-cell Depleted Alternative Donor Transplantation
Wake Forest University Health Sciences
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Memorial Sloan Kettering Cancer Center
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Hoffmann-La Roche
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Incyte Corporation
AFR22
Institut Bergonié
MSC and HSC Coinfusion in Mismatched Minitransplants
University of Liege
MACS0254
Novartis
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Novartis
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
University of Chicago
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
CTI BioPharma
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
M.D. Anderson Cancer Center
OSI-TAR-766
University of Oklahoma
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Fred Hutchinson Cancer Center
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
M.D. Anderson Cancer Center
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
NYU Langone Health
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Mayo Clinic
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center